Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Contrafect (CFRX)

Contrafect (CFRX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 84,939
  • Shares Outstanding, K 15,332
  • Annual Sales, $ 0 K
  • Annual Income, $ -12,790 K
  • 60-Month Beta 1.01
  • Price/Sales N/A
  • Price/Cash Flow 8.94
  • Price/Book 9.81

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate -0.33
  • Number of Estimates 1
  • High Estimate -0.33
  • Low Estimate -0.33
  • Prior Year -0.90
  • Growth Rate Est. (year over year) +63.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.32 +4.14%
on 08/06/20
7.09 -21.86%
on 07/20/20
-1.07 (-16.19%)
since 07/07/20
3-Month
4.45 +24.49%
on 05/22/20
8.00 -30.75%
on 06/25/20
-1.03 (-15.68%)
since 05/07/20
52-Week
2.69 +105.72%
on 08/29/19
13.40 -58.65%
on 01/13/20
+1.36 (+32.60%)
since 08/07/19

Most Recent Stories

More News
ContraFect Announces up to $18.9 Million in Funding from CARB-X to Support Acceleration of the CF-370 Program for Treating Pseudomonas aeruginosa Infections towards Clinical Stage Development

ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical...

CFRX : 5.54 (+0.54%)
Contrafect Announces Publication of Exebacase Phase 2 Study Results in the Journal of Clinical Investigation

Phase 2 study results demonstrated the potential clinical benefit of exebacase, when used in addition to existing antibiotics, for the treatment of life-threatening MRSA bacteremia

CFRX : 5.54 (+0.54%)
ContraFect Announces Appointment of Lishan Aklog, M.D. to Board of Directors

ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical...

CFRX : 5.54 (+0.54%)
PAVM : 2.06 (+1.48%)
ContraFect Corporation Announces Private Placement of Common Stock and Warrants to Pfizer Inc.

ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on discovering and developing direct lytic agents for the treatment of life-threatening infectious diseases, today...

CFRX : 5.54 (+0.54%)
PFE : 38.45 (+0.47%)
ContraFect Corporation Prices Approximately $52.5 Million Public Offering of Common Stock and Warrants

ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on discovering and developing direct lytic agents for the treatment of life-threatening infectious diseases, today...

CFRX : 5.54 (+0.54%)
ContraFect Corporation Announces Proposed Public Offering of Common Stock and Warrants

ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on discovering and developing direct lytic agents for the treatment of life-threatening infectious diseases, today...

CFRX : 5.54 (+0.54%)
ContraFect Reports First Quarter 2020 Financial Results and Provides Business Update

ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical...

CFRX : 5.54 (+0.54%)
ContraFect Announces Four Abstracts Published in the 30th ECCMID Abstract Book

ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical...

CFRX : 5.54 (+0.54%)
ContraFect Announces Dr. Roger J. Pomerantz, Chief Executive Officer and Chairman, Invited as Keynote Speaker and Presenter in Maxim's Infectious Disease Virtual Conference

ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical...

CFRX : 5.54 (+0.54%)
ContraFect to Chair and Participate in Virtual Superbugs & Superdrugs 2020 Conference

ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical...

CFRX : 5.54 (+0.54%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade CFRX with:

Business Summary

ContraFect Corporation is a biotechnology company. The Company is focused on protein and antibody therapeutic products for life-threatening infectious diseases. Its product candidates are CF-301, a lysin for the treatment of Staph aureus bacteremia, and CF-404, a combination of mAbs for the treatment...

See More

Key Turning Points

2nd Resistance Point 5.87
1st Resistance Point 5.71
Last Price 5.54
1st Support Level 5.37
2nd Support Level 5.19

See More

52-Week High 13.40
Fibonacci 61.8% 9.31
Fibonacci 50% 8.05
Fibonacci 38.2% 6.78
Last Price 5.54
52-Week Low 2.69

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar